GLSI.US Greenwich Lifesciences Inc

Healthcare Biotechnology USA Stocks
14.94 USD
Close of Nov 14, 2026
7.78 34.10
Market cap
USD 219M
P/E
-
P/B
71.91x
ROE
-616.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GLSI.US undervalued?

Graham number

The Graham number of Greenwich Lifesciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Greenwich Lifesciences Inc fundamental analysis

No fundamental analysis for Greenwich Lifesciences Inc yet.

Greenwich Lifesciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Greenwich Lifesciences Inc

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficac…

Full company profile